Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by University of Pittsburgh.
Recruitment status was  Recruiting
Information provided by:
University of Pittsburgh Identifier:
First received: June 12, 2006
Last updated: October 2, 2008
Last verified: October 2008
The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will, therefore, be tolerated better than CellCept and also that Myfortic will have a comparable effectiveness to CellCept.

Condition Intervention
Drug: Myfortic

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Conversion of CellCept to Myfortic: A Prospective Study on the Tolerability and Safety of Myfortic in Liver Transplant Recipients

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Incidence and severity of GI adverse events [ Time Frame: 2, 6 and 12 weeks ] [ Designated as safety issue: Yes ]
  • incidence and severity of bone marrow suppression (leukopenia) [ Time Frame: 2, 6 and 12 weeks ] [ Designated as safety issue: Yes ]
  • incidence of cytomegalovirus infection or disease [ Time Frame: 2, 6 and 12 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: November 2006
Estimated Study Completion Date: November 2008
Estimated Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Myfortic
    Myfortic 360mg or 720 mg BID for 90 days.
Detailed Description:
This is a prospective, single center, open-label, safety and tolerability study on the use of Myfortic after liver transplantation. Adult liver transplant patients who are experiencing GI symptoms (nausea, vomiting, diarrhea, abdominal discomfort/pain, dyspepsia) attributable to CellCept are eligible to enter the study. CellCept will be discontinued and replaced with Myfortic. The duration of the study will be 3 months, and during this time, we will assess the incidence and severity of GI adverse events, the incidence and severity of bone marrow suppression (leukopenia), and the incidence of cytomegalovirus (CMV) infection or disease in patients receiving Myfortic.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ALL patients will be adult liver transplant recipients, males or females, 18-80 years of age
  • Patients currently receiving tacrolimus or cyclosporine with or without corticosteroids as part of their immunosuppressive regimen
  • Patients must be receiving CellCept and must have attributable G.I. symptoms (nausea, vomiting, diarrhea, abdominal discomfort/pain, dyspepsia)
  • Patients must be more than 30 days post-transplant to be eligible
  • Females of childbearing potential must have a negative serum pregnancy test prior to the inclusion period

Exclusion Criteria:

  • Multi-organ transplant patients
  • HIV positive patients.
  • Living-related liver transplant recipients
  • Pregnant patients
  • Patients with a history of extra-hepatic malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin
  • Patients with thrombocytopenia (<50,000/mm3), with an absolute neutrophil count of <1,000/mm3 and/or leukocytopenia (<2,000/mm3), and/or hemoglobin <7.0 g/dL prior to enrollment
  • Patients with a G.I. clinical problem at the time of enrollment (e.g. CMV infection or disease, C. difficile colitis, active peptic ulcer disease, gastroenteritis, inflammatory bowel disease)
  • Presence of clinically significant infection requiring continued therapy or uncontrolled diabetes mellitus
  • Evidence of drug and/or alcohol abuse
  • Decisionally impaired subjects who are not medically or mentally capable of providing consent themselves
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00336895

Contact: Michael E de Vera, MD 412-647-5174
Contact: Laurie K Hope, RN 412-692-2208

United States, Pennsylvania
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Michael E de Vera, MD    412-647-5174   
Contact: Laurie K Hope, RN    412-692-2208   
Principal Investigator: Michael E de Vera, MD         
Sub-Investigator: J. Wallis Marsh, MD`         
Sub-Investigator: Paulo Fontes, MD         
Sub-Investigator: Kyle Soltys, MD         
Sub-Investigator: Roberto Lopez, MD         
Sub-Investigator: Deanna Blisard, MD         
Sub-Investigator: Vinay Kumaran, MD         
Sub-Investigator: Igor Dvorchik, MD         
Sub-Investigator: Raman Venkataramanan, MD         
Sub-Investigator: Barbara Yelochan, MD         
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Michael E de Vera, MD University of Pittsburgh
  More Information

Responsible Party: Michael de Vera, M.D., UPMC Identifier: NCT00336895     History of Changes
Other Study ID Numbers: CERL080A-US27 
Study First Received: June 12, 2006
Last Updated: October 2, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
Liver transplantation
mycophenolate mofetil
adverse effects

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on October 21, 2016